Autonomix Signs Key Clinical Agreements in Preparation to Begin March 2024 Human Clinical Trial
THE WOODLANDS, TX, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced it has entered into a clinical site agreement with “АКFА MEDLINE" Ltd., for its PoC human clinical trial evaluating the use of transvascular RF ablation for the treatment of pancreatic cancer pain.
- Additionally, Autonomix announced the selection of Clinical Accelerator and Qmed, full service Clinical Research Organizations (CROs) specializing in medical devices to support the PoC human clinical trial.
- Clinical Accelerator will be responsible for managing the clinical operations in country, including recruiting patients, SIV work, and patient treatment records and Qmed will be responsible for managing protocol and trial reporting, as well as managing patient data.
- Lori Bisson, Chief Executive Officer of Autonomix commented, “We are pleased to execute these important agreements and final steps towards commencing patient enrollment in our first PoC human clinical trial.
- Twenty (20) subjects will be enrolled at one clinical trial site for the trial.